{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-019718","form_type":"8-K","ticker":"AYTU","cik":"0001385818","company_name":"AYTU BIOPHARMA, INC","filed_at":"2025-06-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.130278+00:00","generated_at":"2026-05-19T18:12:57.122095+00:00","sec_items":["1.01","2.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Aytu BioPharma secures exclusive U.S. commercialization rights to EXXUA (gepirone) for MDD","bullets":["Upfront cash payment of $3M; second payment of $3M due 1-year post-launch, increasing to $5M if first-year net sales exceed $35M.","Royalty on net sales starts at 28%, steps up to 39% when annual net sales surpass $300M; lower tier after trigger at 24.5%-35.5%.","Milestone payments range from $5M to over $100M per year based on net sales thresholds; 10% royalty on sales above $1B.","EXXUA is a first-in-class 5HT1a receptor agonist for MDD with no sexual dysfunction label warning; launch targeted for Q4 2025.","Transaction funded by cash on hand and institutional investors including Nantahala Capital, Stonepine Capital, and Aytu management."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-019718","json":"https://secwatch.observer/filing/0001437749-25-019718.json","markdown":"https://secwatch.observer/filing/0001437749-25-019718.md","text":"https://secwatch.observer/filing/0001437749-25-019718.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1385818/000143774925019718/0001437749-25-019718-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1385818/000143774925019718/aytu20250523c_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T18:12:57.122095+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}